• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

猪和人类小肠中胰高血糖素原111 - 160的天然产物。

Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine.

作者信息

Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst J J

机构信息

Institute of Medical Physiology C, Panum Institute, Copenhagen, Denmark.

出版信息

J Biol Chem. 1988 Jun 25;263(18):8621-4.

PMID:3379036
Abstract

Recent studies have revealed that the glucagon gene is expressed in the mammalian intestine. Here it codes for "glicentin" (proglucagon 1-69) and a glucagon-like peptide, proglucagon 78-107, recently isolated from porcine intestine. We studied the fate of the remaining COOH-terminal part of proglucagon (proglucagon 111-160) using radioimmunoassays against proglucagon 111-123 and 126-160. Two peptides were isolated from acid ethanol extracts of porcine ileal mucosa and sequenced: one corresponding to proglucagon 126-158 and one probably corresponding to proglucagon 111-158. By comparing human and porcine proglucagon sequences, Ala117 is replaced by Thr, and Ile138, Ala144, Ile152 and Gln153 are replaced by Val, Thr, Leu, and His. By gel filtration and radioimmunoassay of intestinal extracts it was established that a large part of porcine and virtually all of human proglucagon are processed to release proglucagon 111-123 (designated spacer peptide 2), which, like proglucagon 126-158 must be considered a potential hormonal entity. By isocratic high pressure liquid chromatography human spacer peptide 2 was indistinguishable from synthetic proglucagon 111-122 amide, suggesting that this is the structure of the naturally occurring human peptide.

摘要

最近的研究表明,胰高血糖素基因在哺乳动物肠道中表达。在这里,它编码“肠高血糖素”(胰高血糖素原1 - 69)和一种类胰高血糖素肽,即最近从猪肠道中分离出的胰高血糖素原78 - 107。我们使用针对胰高血糖素原111 - 123和126 - 160的放射免疫分析法,研究了胰高血糖素原剩余的COOH末端部分(胰高血糖素原111 - 160)的去向。从猪回肠黏膜的酸性乙醇提取物中分离出两种肽并进行测序:一种对应于胰高血糖素原126 - 158,另一种可能对应于胰高血糖素原111 - 158。通过比较人和猪的胰高血糖素原序列,发现丙氨酸117被苏氨酸取代,异亮氨酸138、丙氨酸144、异亮氨酸152和谷氨酰胺153分别被缬氨酸、苏氨酸、亮氨酸和组氨酸取代。通过对肠道提取物进行凝胶过滤和放射免疫分析,确定猪的大部分以及几乎所有的人胰高血糖素原都被加工释放出胰高血糖素原111 - 123(称为间隔肽2),它与胰高血糖素原126 - 158一样,必须被视为一种潜在的激素实体。通过等度高压液相色谱法,人间隔肽2与合成的胰高血糖素原111 - 122酰胺无法区分,这表明这就是天然存在的人肽的结构。

相似文献

1
Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine.猪和人类小肠中胰高血糖素原111 - 160的天然产物。
J Biol Chem. 1988 Jun 25;263(18):8621-4.
2
Glicentin is present in the pig pancreas.胰高血糖素样肽存在于猪的胰腺中。
FEBS Lett. 1985 Jan 1;179(1):1-6. doi: 10.1016/0014-5793(85)80178-2.
3
Proglucagon processing in porcine and human pancreas.猪和人胰腺中胰高血糖素原的加工处理
J Biol Chem. 1994 Jul 22;269(29):18827-33.
4
Pancreatic and intestinal processing of proglucagon in man.人体内胰高血糖素原的胰腺和肠道加工过程。
Diabetologia. 1987 Nov;30(11):874-81. doi: 10.1007/BF00274797.
5
Human colon produces fully processed glucagon-like peptide-1 (7-36) amide.人类结肠可产生完全加工的胰高血糖素样肽-1(7-36)酰胺。
FEBS Lett. 1995 Sep 25;372(2-3):269-72. doi: 10.1016/0014-5793(95)00983-g.
6
The primary structure of porcine glicentin (proglucagon).猪胰高血糖素原(胰高血糖素原)的一级结构。
Regul Pept. 1981 May;2(2):139-50. doi: 10.1016/0167-0115(81)90007-0.
7
Purification and chemical characterization of a glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreas.从猪胰腺中纯化和化学表征一种胰高血糖素相关胰肽(胰高血糖素原片段)
Biochim Biophys Acta. 1982 May 3;703(2):134-41. doi: 10.1016/0167-4838(82)90041-3.
8
Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas.胰高血糖素样肽I的酰胺化和非酰胺化形式均在大鼠肠道和胰腺中合成。
J Biol Chem. 1990 May 15;265(14):8001-8.
9
Glucagon-related peptides in the human gastrointestinal mucosa.人类胃肠道黏膜中的胰高血糖素相关肽
Diabetologia. 1984 Mar;26(3):223-8. doi: 10.1007/BF00252412.
10
Isolation and chemical characterization of glicentin C-terminal hexapeptide in porcine pancreas.猪胰腺中胰高血糖素原C端六肽的分离与化学表征
FEBS Lett. 1985 Sep 9;189(1):50-6. doi: 10.1016/0014-5793(85)80840-1.

引用本文的文献

1
Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.2024年年度获奖讲座:作为肥胖症和2型糖尿病治疗基础的内源性生理机制
J Physiol. 2024 Dec;602(24):6613-6629. doi: 10.1113/JP287461. Epub 2024 Nov 9.
2
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.肥胖中的胰高血糖素样肽-1生理机制及用于慢性体重管理的肠促胰岛素类药物的研发。
Nat Metab. 2024 Oct;6(10):1866-1885. doi: 10.1038/s42255-024-01113-9. Epub 2024 Aug 19.
3
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
一种名为 retatrutide 的在研药物的综述,这是一种新型三重激动剂药物,用于治疗肥胖症。
Eur J Clin Pharmacol. 2024 May;80(5):669-676. doi: 10.1007/s00228-024-03646-0. Epub 2024 Feb 17.
4
Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity.胰高血糖素及其他胰高血糖素原衍生肽在肥胖发病机制中的作用
Front Nutr. 2022 Aug 4;9:964406. doi: 10.3389/fnut.2022.964406. eCollection 2022.
5
Discovery of the GI Effects of GLP-1: An Historical Perspective.GLP-1 的胃肠道作用的发现:历史视角。
Dig Dis Sci. 2022 Jul;67(7):2716-2720. doi: 10.1007/s10620-022-07519-3. Epub 2022 May 30.
6
Actions of glucagon-like peptide-1 receptor ligands in the gut.胰高血糖素样肽-1 受体配体在肠道中的作用。
Br J Pharmacol. 2022 Feb;179(4):727-742. doi: 10.1111/bph.15611. Epub 2021 Aug 4.
7
Proglucagon-Derived Peptides as Therapeutics.胰高血糖素原衍生肽类作为治疗药物。
Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. eCollection 2021.
8
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.大鼠亚慢性给予GIP受体拮抗剂而非GLP-2受体拮抗剂后体重和脂肪量增加。
Front Endocrinol (Lausanne). 2019 Aug 6;10:492. doi: 10.3389/fendo.2019.00492. eCollection 2019.
9
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy.从肠促胰岛素概念和GLP-1的发现到当今的糖尿病治疗
Front Endocrinol (Lausanne). 2019 Apr 26;10:260. doi: 10.3389/fendo.2019.00260. eCollection 2019.
10
Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment.肠道激素及其对骨代谢的影响。未来骨质疏松症治疗中的潜在药物疗法。
Front Endocrinol (Lausanne). 2019 Feb 26;10:75. doi: 10.3389/fendo.2019.00075. eCollection 2019.